Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Sleep Initiation and Maintenance Disorders HELP
Based on 5,473 articles published since 2007
||||

These are the 5473 published articles about Sleep Initiation and Maintenance Disorders that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline European guideline for the diagnosis and treatment of insomnia. 2017

Riemann, Dieter / Baglioni, Chiara / Bassetti, Claudio / Bjorvatn, Bjørn / Dolenc Groselj, Leja / Ellis, Jason G / Espie, Colin A / Garcia-Borreguero, Diego / Gjerstad, Michaela / Gonçalves, Marta / Hertenstein, Elisabeth / Jansson-Fröjmark, Markus / Jennum, Poul J / Leger, Damien / Nissen, Christoph / Parrino, Liborio / Paunio, Tiina / Pevernagie, Dirk / Verbraecken, Johan / Weeß, Hans-Günter / Wichniak, Adam / Zavalko, Irina / Arnardottir, Erna S / Deleanu, Oana-Claudia / Strazisar, Barbara / Zoetmulder, Marielle / Spiegelhalder, Kai. ·Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. · University Hospital for Neurology, Inselspital Bern, Bern, Switzerland. · Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. · Institute of Clinical Neurophysiology, University Medical Center Ljubljana, Ljubljana, Slovenia. · Northumbria Sleep Research Laboratory, Northumbria University, Newcastle, UK. · Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neuroscience at the University of Oxford, Oxford, UK. · Sleep Research Institute Madrid, Madrid, Spain. · Stavanger University Hospital, Stavanger, Norway. · Centro de Medicina de Sono, Hospital Cuf, Porto, Portugal. · Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. · Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. · Centre du Sommeil et de la Vigilance et EA 7330 VIFASOM, Université Paris Descartes, Clinic Hotel-Dieu, Sorbonne Paris Cité, APHP, HUPC, Hotel Dieu de Paris, Paris, France. · Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; University Hospital for Neurology, Inselspital Bern, Bern, Switzerland.; University Hospital of Psychiatry, Bern, Switzerland. · Department of Medicine and Surgery, University of Parma, Parma, Italy. · National Institute for Health and Welfare Helsinki, Helsinki, Finland. · Sleep Medicine Centre, Kempenhaeghe Foundation, Heeze, The Netherlands. · Multidisciplinary Sleep Disorders Centre, Antwerp University Hospital and University of Antwerp, Edegem-Wilrijk, Belgium. · Sleep Center Pfalzklinikum, Klingenmünster, Germany. · Sleep Medicine Center and Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland. · Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency, Moscow, Russia. · Sleep Measurements, National University Hospital of Iceland, Reykjavik, Iceland. · Institute for Pneumology, Medical Faculty, University of Bucharest, Bucharest, Romania. · Centre for Sleep Disorders in Children and Adolescents, General Hospital Celje, Ljubljana, Slovenia. · Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. ·J Sleep Res · Pubmed #28875581.

ABSTRACT: This European guideline for the diagnosis and treatment of insomnia was developed by a task force of the European Sleep Research Society, with the aim of providing clinical recommendations for the management of adult patients with insomnia. The guideline is based on a systematic review of relevant meta-analyses published till June 2016. The target audience for this guideline includes all clinicians involved in the management of insomnia, and the target patient population includes adults with chronic insomnia disorder. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system was used to grade the evidence and guide recommendations. The diagnostic procedure for insomnia, and its co-morbidities, should include a clinical interview consisting of a sleep history (sleep habits, sleep environment, work schedules, circadian factors), the use of sleep questionnaires and sleep diaries, questions about somatic and mental health, a physical examination and additional measures if indicated (i.e. blood tests, electrocardiogram, electroencephalogram; strong recommendation, moderate- to high-quality evidence). Polysomnography can be used to evaluate other sleep disorders if suspected (i.e. periodic limb movement disorder, sleep-related breathing disorders), in treatment-resistant insomnia, for professional at-risk populations and when substantial sleep state misperception is suspected (strong recommendation, high-quality evidence). Cognitive behavioural therapy for insomnia is recommended as the first-line treatment for chronic insomnia in adults of any age (strong recommendation, high-quality evidence). A pharmacological intervention can be offered if cognitive behavioural therapy for insomnia is not sufficiently effective or not available. Benzodiazepines, benzodiazepine receptor agonists and some antidepressants are effective in the short-term treatment of insomnia (≤4 weeks; weak recommendation, moderate-quality evidence). Antihistamines, antipsychotics, melatonin and phytotherapeutics are not recommended for insomnia treatment (strong to weak recommendations, low- to very-low-quality evidence). Light therapy and exercise need to be further evaluated to judge their usefulness in the treatment of insomnia (weak recommendation, low-quality evidence). Complementary and alternative treatments (e.g. homeopathy, acupuncture) are not recommended for insomnia treatment (weak recommendation, very-low-quality evidence).

2 Guideline Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. 2017

Sateia, Michael J / Buysse, Daniel J / Krystal, Andrew D / Neubauer, David N / Heald, Jonathan L. ·Geisel School of Medicine at Dartmouth, Hanover, NH. · University of Pittsburgh School of Medicine, Pittsburgh, PA. · University of California, San Francisco, San Francisco, CA. · Johns Hopkins University School of Medicine, Baltimore, MD. · American Academy of Sleep Medicine, Darien, IL. ·J Clin Sleep Med · Pubmed #27998379.

ABSTRACT: INTRODUCTION: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. METHODS: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. Literature reviews are provided for those pharmacologic agents for which sufficient evidence was available to establish recommendations. The AASM Board of Directors approved the final recommendations. RECOMMENDATIONS: The following recommendations are intended as a guideline for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults, when such treatment is indicated. Under GRADE, a STRONG recommendation is one that clinicians should, under most circumstances, follow. A WEAK recommendation reflects a lower degree of certainty in the outcome and appropriateness of the patient-care strategy for all patients, but should not be construed as an indication of ineffectiveness. GRADE recommendation strengths do not refer to the magnitude of treatment effects in a particular patient, but rather, to the strength of evidence in published data. Downgrading the quality of evidence for these treatments is predictable in GRADE, due to the funding source for most pharmacological clinical trials and the attendant risk of publication bias; the relatively small number of eligible trials for each individual agent; and the observed heterogeneity in the data. The ultimate judgment regarding propriety of any specific care must be made by the clinician in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources. We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use triazolam as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use temazepam as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use ramelteon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use doxepin as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tiagabine as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use diphenhydramine as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tryptophan as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK).

3 Guideline Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. 2016

Qaseem, Amir / Kansagara, Devan / Forciea, Mary Ann / Cooke, Molly / Denberg, Thomas D / Anonymous4310942. · ·Ann Intern Med · Pubmed #27136449.

ABSTRACT: DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of chronic insomnia disorder in adults. METHODS: This guideline is based on a systematic review of randomized, controlled trials published in English from 2004 through September 2015. Evaluated outcomes included global outcomes assessed by questionnaires, patient-reported sleep outcomes, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with chronic insomnia disorder. This guideline grades the evidence and recommendations by using the ACP grading system, which is based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. RECOMMENDATION 1: ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. (Grade: strong recommendation, moderate-quality evidence). RECOMMENDATION 2: ACP recommends that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy for insomnia (CBT-I) alone was unsuccessful. (Grade: weak recommendation, low-quality evidence).

4 Guideline Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. 2015

Asnis, Gregory M / Thomas, Manju / Henderson, Margaret A. ·Albert Einstein College of Medicine/Montefiore Medical Center, Department of Psychiatry & Behavioral Science, Bronx, NY 10467, USA. asnisarts@aol.com.; The Anxiety and Depression Clinic, Bronx, NY 10570, USA. asnisarts@aol.com. · The Anxiety and Depression Clinic, Bronx, NY 10570, USA. manju.thomas3@gmail.com. · The Anxiety and Depression Clinic, Bronx, NY 10570, USA. mahg96@aol.com. ·Int J Mol Sci · Pubmed #26729104.

ABSTRACT: Insomnia is a prevalent disorder with deleterious effects such as decreased quality of life, and a predisposition to a number of psychiatric disorders. Fortunately, numerous approved hypnotic treatments are available. This report reviews the state of the art of pharmacotherapy with a reference to cognitive behavioral therapy for insomnia (CBT-I) as well. It provides the clinician with a guide to all the Food and Drug Administration (FDA) approved hypnotics (benzodiazepines, nonbenzodiazepines, ramelteon, low dose sinequan, and suvorexant) including potential side effects. Frequently, chronic insomnia lasts longer than 2 years. Cognizant of this and as a result of longer-term studies, the FDA has approved all hypnotics since 2005 without restricting the duration of use. Our manuscript also reviews off-label hypnotics (sedating antidepressants, atypical antipsychotics, anticonvulsants and antihistamines) which in reality, are more often prescribed than approved hypnotics. The choice of which hypnotic to choose is discussed partially being based on which segment of sleep is disturbed and whether co-morbid illnesses exist. Lastly, we discuss recent label changes required by the FDA inserting a warning about "sleep-related complex behaviors", e.g., sleep-driving for all hypnotics. In addition, we discuss FDA mandated dose reductions for most zolpidem preparations in women due to high zolpidem levels in the morning hours potentially causing daytime carry-over effects.

5 Guideline [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly]. 2014

Medina-Chávez, Juan Humberto / Fuentes-Alexandro, Salvador Amadeo / Gil-Palafox, Irwin Bernardo / Adame-Galván, Lorena / Solís-Lam, Fernando / Sánchez-Herrera, Lucía Yveth / Sánchez-Narváez, Francisco / Anonymous710788. ·División de Excelencia Clínica, Coordinación de Unidades Médicas de Alta Especialidad, Instituto Mexicano del Seguro Social, Distrito Federal, México. humberto.medina@imss.gob.mx. · ·Rev Med Inst Mex Seguro Soc · Pubmed #24625494.

ABSTRACT: Insomnia is the difficulty to initiate or to maintain sleep. It also has to do with waking up too early at least for a month. A patient with insomnia has daytime consequences such as fatigue, sleepiness, changes in mood, lose of concentration, as well as changes in his social performance and his family relationships, among others. The relationship between this disorder and physical and mental health is important due to the impact that it has on the quality of life and life expectancy of those who suffer from it. Unfortunately, insomnia usually goes unnoticed or untreated, which contributes to the onset or worsening of psychiatric and medical conditions. This exacerbates the problem of insomnia in the elderly people. In relation to the treatment it is recommended: 1) the search and management of secondary causes of insomnia, 2) a non-drug therapy that includes sleep hygiene measures, 3) pharmacotherapy. It is not recommended to start a treatment with a hypnotic drug without rule out medications or diseases that cause or exacerbate insomnia. It is not recommended the use of narcoleptics, melatonin, antihistamines or long half-life benzodiazepines. The consequences include limitations on activities of daily living, loss of functionality, impaired quality of life, increased morbidity and mortality, as well as the worsening of preexisting chronic conditions.

6 Guideline A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer. 2013

Howell, Doris / Oliver, Thomas K / Keller-Olaman, Sue / Davidson, Judith / Garland, Sheila / Samuels, Charles / Savard, Josée / Harris, Cheryl / Aubin, Michèle / Olson, Karin / Sussman, Jonathan / Macfarlane, James / Taylor, Claudette / Anonymous3580759. ·University Health Network (Princess Margaret Hospital), 610 University Avenue PMH, Room 15-617, Toronto, ON, Canada, doris.howell@uhn.on.ca. · ·Support Care Cancer · Pubmed #23708820.

ABSTRACT: PURPOSE: This study aims to provide recommendations on the optimal strategies and interventions for the prevention, screening, assessment, and management of cancer-related sleep disturbance (insomnia and insomnia syndrome) in adult cancer populations. METHODS: A systematic search of the published health literature was conducted to identify randomized controlled trials, clinical practice guidelines, systematic reviews, and other guidance documents. The Sleep Disturbance Expert Panel [comprised of nurses, psychologists, primary care physicians, oncologists, physicians specialized in sleep disturbances, researchers, and guideline methodologists] reviewed, discussed, and approved the final version of the guideline. Health care professionals across Canada were asked to provide feedback through an external review process. RESULTS: Three clinical practice guidelines and 12 randomized controlled trials were identified as the evidence base. Overall, despite the paucity of evidence, the evidence and expert consensus suggest that it is important to screen and assess adult cancer patients for sleep disturbances using standardized screening tools on a routine basis. While prevention of sleep disturbance is the desired objective, cognitive behavioral therapies are effective in improving sleep outcomes. As part of the external review with 16 health care providers, 81 % indicated that they agreed with the recommendations as written. CONCLUSIONS: Sleep difficulty is a prevalent problem in cancer populations that needs greater recognition by health professionals. Prevention, screening, assessment, and treatment strategies supported by the best available evidence are critical. Recommendations and care path algorithms for practice are offered.

7 Guideline A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. 2012

Malow, Beth A / Byars, Kelly / Johnson, Kyle / Weiss, Shelly / Bernal, Pilar / Goldman, Suzanne E / Panzer, Rebecca / Coury, Daniel L / Glaze, Dan G / Anonymous1570741. ·Departments of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. beth.malow@vanderbilt.edu · ·Pediatrics · Pubmed #23118242.

ABSTRACT: OBJECTIVE: This report describes the development of a practice pathway for the identification, evaluation, and management of insomnia in children and adolescents who have autism spectrum disorders (ASDs). METHODS: The Sleep Committee of the Autism Treatment Network (ATN) developed a practice pathway, based on expert consensus, to capture best practices for an overarching approach to insomnia by a general pediatrician, primary care provider, or autism medical specialist, including identification, evaluation, and management. A field test at 4 ATN sites was used to evaluate the pathway. In addition, a systematic literature review and grading of evidence provided data regarding treatments of insomnia in children who have neurodevelopmental disabilities. RESULTS: The literature review revealed that current treatments for insomnia in children who have ASD show promise for behavioral/educational interventions and melatonin trials. However, there is a paucity of evidence, supporting the need for additional research. Consensus among the ATN sleep medicine committee experts included: (1) all children who have ASD should be screened for insomnia; (2) screening should be done for potential contributing factors, including other medical problems; (3) the need for therapeutic intervention should be determined; (4) therapeutic interventions should begin with parent education in the use of behavioral approaches as a first-line approach; (5) pharmacologic therapy may be indicated in certain situations; and (6) there should be follow-up after any intervention to evaluate effectiveness and tolerance of the therapy. Field testing of the practice pathway by autism medical specialists allowed for refinement of the practice pathway. CONCLUSIONS: The insomnia practice pathway may help health care providers to identify and manage insomnia symptoms in children and adolescents who have ASD. It may also provide a framework to evaluate the impact of contributing factors on insomnia and to test the effectiveness of nonpharmacologic and pharmacologic treatment strategies for the nighttime symptoms and daytime functioning and quality of life in ASD.

8 Guideline New guidelines for diagnosis and treatment of insomnia. 2010

Pinto Jr, Luciano Ribeiro / Alves, Rosana Cardoso / Caixeta, Eliazor / Fontenelle, John Araujo / Bacellar, Andrea / Poyares, Dalva / Aloe, Flavio / Rizzo, Geraldo / Minhoto, Gisele / Bittencourt, Lia Rita / Ataide, Luiz / Assis, Márcia / Pradella-Hallinan, Márcia / Pinto, Maria Christina Ribeiro / Rodrigues, Raimundo Nonato D / Hasan, Rosa / Fonseca, Ronaldo / Tavares, Stella. ·Brazilian Sleep Association, São Paulo, SP, Brazil. luciano@psicobio.epm.br · ·Arq Neuropsiquiatr · Pubmed #20730332.

ABSTRACT: The Brazilian Sleep Association brought together specialists in sleep medicine, in order to develop new guidelines on the diagnosis and treatment of insomnias. The following subjects were discussed: concepts, clinical and psychosocial evaluations, recommendations for polysomnography, pharmacological treatment, behavioral and cognitive therapy, comorbidities and insomnia in children. Four levels of evidence were envisaged: standard, recommended, optional and not recommended. For diagnosing of insomnia, psychosocial and polysomnographic investigation were recommended. For non-pharmacological treatment, cognitive behavioral treatment was considered to be standard, while for pharmacological treatment, zolpidem was indicated as the standard drug because of its hypnotic profile, while zopiclone, trazodone and doxepin were recommended.

9 Guideline Clinical guideline for the evaluation and management of chronic insomnia in adults. 2008

Schutte-Rodin, Sharon / Broch, Lauren / Buysse, Daniel / Dorsey, Cynthia / Sateia, Michael. ·Penn Sleep Centers, University of Pennsylvania Health System, Philadelphia, PA 19104, USA. rodins@hphs.upenn.edu · ·J Clin Sleep Med · Pubmed #18853708.

ABSTRACT: Insomnia is the most prevalent sleep disorder in the general population, and is commonly encountered in medical practices. Insomnia is defined as the subjective perception of difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep, and that results in some form of daytime impairment.1 Insomnia may present with a variety of specific complaints and etiologies, making the evaluation and management of chronic insomnia demanding on a clinician's time. The purpose of this clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist. Unless otherwise stated, "insomnia" refers to chronic insomnia, which is present for at least a month, as opposed to acute or transient insomnia, which may last days to weeks.

10 Editorial Sleepless in America: Burning the Candle at Both Ends? At What Cost? 2016

Gaines, Kaye K. · ·Urol Nurs · Pubmed #27501590.

ABSTRACT: -- No abstract --

11 Editorial Insomnia in Heart Failure. 2016

Tsuchihashi-Makaya, Miyuki / Matsuoka, Shiho. ·School of Nursing, Kitasato University. · ·Circ J · Pubmed #27264415.

ABSTRACT: -- No abstract --

12 Editorial An Update on Sleep and Sedation Issues in Critical Care. 2016

Foster, Jan. ·Nursing Inquiry and Intervention, Inc, The Woodlands, TX 77381, USA. Electronic address: jgwfoster@comcast.net. ·Crit Care Nurs Clin North Am · Pubmed #27215363.

ABSTRACT: -- No abstract --

13 Editorial Cognitive Behavioral Therapy for Chronic Insomnia: Confronting the Challenges to Implementation. 2016

Kathol, Roger G / Arnedt, J Todd. · ·Ann Intern Med · Pubmed #27136604.

ABSTRACT: -- No abstract --

14 Editorial The need to address increasing opioid use in elderly COPD patients. 2016

Vozoris, Nicholas T / O'Donnell, Denis E. ·a Division of Respirology, Department of Medicine , St. Michael's Hospital , Toronto , ON , Canada.; b Keenan Research Centre in the Li Ka Shing Knowledge Institute , St Michael's Hospital , Toronto , ON , Canada.; c Department of Medicine , University of Toronto , Toronto , ON , Canada. · d Department of Medicine , Queen's University , Kingston , ON , Canada. ·Expert Rev Respir Med · Pubmed #26783198.

ABSTRACT: -- No abstract --

15 Editorial Integrative medicine: A primer. 2015

Hillinger, Marni G. ·Department of Physical Medicine and Rehabilitation , Osher Center for Integrative Medicine at Vanderbilt , Nashville, TN, USA. ·Cranio · Pubmed #26825193.

ABSTRACT: -- No abstract --

16 Editorial Do Sleep Disorders Predispose to the Development of Type 2 Diabetes Mellitus? 2015

Sharma, S K / Jha, Saket. · ·Indian J Chest Dis Allied Sci · Pubmed #26591966.

ABSTRACT: -- No abstract --

17 Editorial A commentary on the "Functioning of three attentional networks and vigilance in primary insomnia". 2015

Perlis, Michael L / Roalf, David R / Kloss, Jaqueline D. ·Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, USA. Electronic address: mperlis@upenn.edu. · Neuropsychiatry Section, Department of Psychiatry, University of Pennsylvania, USA. · Department of Psychology, Drexel University, USA. ·Sleep Med · Pubmed #26459678.

ABSTRACT: -- No abstract --

18 Editorial Differential effect of depression versus thermoregulation in postmenopausal sleep disturbance. 2015

Parry, Barbara L. · ·Menopause · Pubmed #26263284.

ABSTRACT: -- No abstract --

19 Editorial Could networking and sharing (open) data in an international collaborative effort unravel the mechanisms of sleep disturbances in middle-aged women? 2015

Carrier, Julie / Lord, Catherine. ·Department of Psychology, Université de Montréal Montreal, Quebec, Canada Center for Advanced Research in Sleep Medicine Research Center of the Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada Research Center, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada. · ·Menopause · Pubmed #26079970.

ABSTRACT: -- No abstract --

20 Editorial Cognitive Behavioral Therapy for Chronic Insomnia: State of the Science Versus Current Clinical Practices. 2015

Morin, Charles M. · ·Ann Intern Med · Pubmed #26052868.

ABSTRACT: -- No abstract --

21 Editorial Insomnia and excessive daytime sleepiness in obstructive sleep apnea: only different clinical phenotypes? 2015

Mermigkis, Charalampos / Bouloukaki, Izolde / Schiza, Sophia E. ·Sleep Disorders Unit, Department of Thoracic Medicine, University General Hospital, Medical School of the University of Crete, Crete, Greece. mermigh@gmail.com.; Sleep Disorders Center, 401 General Army Hospital, Thrakis 61A, Vrilissia, Athens, Greece. mermigh@gmail.com.; Sleep Disorders Center, Henry Dunant Hospital, Athens, Greece. mermigh@gmail.com. · Sleep Disorders Unit, Department of Thoracic Medicine, University General Hospital, Medical School of the University of Crete, Crete, Greece. ·Sleep Breath · Pubmed #25855472.

ABSTRACT: -- No abstract --

22 Editorial Insomnia research--Time for "fine-tuning". 2015

Riemann, Dieter / Spiegelhalder, Kai. ·Department of Clinical Psychology and Psychophysiology, Center for Mental Disorders, Freiburg University Medical Center, Hauptstrasse 5, 79104 Freiburg, Germany. Electronic address: dieter.riemann@uniklinik-freiburg.de. · Department of Clinical Psychology and Psychophysiology, Center for Mental Disorders, Freiburg University Medical Center, Hauptstrasse 5, 79104 Freiburg, Germany. ·Sleep Med Rev · Pubmed #25794842.

ABSTRACT: -- No abstract --

23 Editorial Insomnia symptoms predict physical and mental impairments among postmenopausal women. 2015

Grandner, Michael A / Nowakowski, Sara / Kloss, Jacqueline D / Perlis, Michael L. ·Behavioral Sleep Medicine Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: grandner@gmail.com. · Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA. · Department of Psychology, Drexel University, Philadelphia, PA, USA. · Behavioral Sleep Medicine Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, USA. ·Sleep Med · Pubmed #25698406.

ABSTRACT: -- No abstract --

24 Editorial What if? 2015

McCall, W Vaughn. ·From the Department of Psychiatry and Health Behavior, Georgia Regents University, Augusta, GA. ·J ECT · Pubmed #25627212.

ABSTRACT: -- No abstract --

25 Editorial Increased sleep need and daytime sleepiness 6 months after traumatic brain injury: a prospective controlled clinical trial. 2015

Imbach, Lukas L / Valko, Philipp O / Li, Tongzhou / Maric, Angelina / Symeonidou, Evangelia-Regkina / Stover, John F / Bassetti, Claudio L / Mica, Ladislav / Werth, Esther / Baumann, Christian R. ·1 Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland christian.baumann@usz.ch. · 1 Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland. · 2 Department of Traumatology, University Hospital Zurich, 8091 Zurich, Switzerland. · 3 Department of Neurology, Inselspital Bern, 3010 Bern, Switzerland. ·Brain · Pubmed #25595147.

ABSTRACT: Post-traumatic sleep-wake disturbances are common after acute traumatic brain injury. Increased sleep need per 24 h and excessive daytime sleepiness are among the most prevalent post-traumatic sleep disorders and impair quality of life of trauma patients. Nevertheless, the relation between traumatic brain injury and sleep outcome, but also the link between post-traumatic sleep problems and clinical measures in the acute phase after traumatic brain injury has so far not been addressed in a controlled and prospective approach. We therefore performed a prospective controlled clinical study to examine (i) sleep-wake outcome after traumatic brain injury; and (ii) to screen for clinical and laboratory predictors of poor sleep-wake outcome after acute traumatic brain injury. Forty-two of 60 included patients with first-ever traumatic brain injury were available for follow-up examinations. Six months after trauma, the average sleep need per 24 h as assessed by actigraphy was markedly increased in patients as compared to controls (8.3 ± 1.1 h versus 7.1 ± 0.8 h, P < 0.0001). Objective daytime sleepiness was found in 57% of trauma patients and 19% of healthy subjects, and the average sleep latency in patients was reduced to 8.7 ± 4.6 min (12.1 ± 4.7 min in controls, P = 0.0009). Patients, but not controls, markedly underestimated both excessive sleep need and excessive daytime sleepiness when assessed only by subjective means, emphasizing the unreliability of self-assessment of increased sleep propensity in traumatic brain injury patients. At polysomnography, slow wave sleep after traumatic brain injury was more consolidated. The most important risk factor for developing increased sleep need after traumatic brain injury was the presence of an intracranial haemorrhage. In conclusion, we provide controlled and objective evidence for a direct relation between sleep-wake disturbances and traumatic brain injury, and for clinically significant underestimation of post-traumatic sleep-wake disturbances by trauma patients.

Next